Kamada (NASDAQ:KMDA) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a buy rating in a report issued on Tuesday, Zacks.com reports. The firm currently has $6.50 price objective on the biotechnology company’s stock.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Separately, Chardan Capital set a $8.00 price objective on shares of OncoCyte and gave the stock a buy rating in a research note on Friday, May 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $8.17.
Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.08. The firm had revenue of $26.80 million for the quarter, compared to analyst estimates of $22.87 million. Kamada had a net margin of 20.97% and a return on equity of 24.75%. Research analysts anticipate that Kamada will post 0.51 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC lifted its holdings in Kamada by 41.8% during the first quarter. Acadian Asset Management LLC now owns 945,878 shares of the biotechnology company’s stock valued at $5,422,000 after purchasing an additional 278,674 shares in the last quarter. Meitav Dash Investments Ltd. lifted its holdings in Kamada by 3.1% during the first quarter. Meitav Dash Investments Ltd. now owns 909,912 shares of the biotechnology company’s stock valued at $5,201,000 after purchasing an additional 27,405 shares in the last quarter. Marshall Wace LLP purchased a new position in Kamada during the first quarter valued at $276,000. Norges Bank purchased a new position in Kamada during the fourth quarter valued at $219,000. Finally, Nkcfo LLC purchased a new position in Kamada during the first quarter valued at $26,000. 12.98% of the stock is currently owned by institutional investors and hedge funds.
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.